Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
出版年份 2021 全文链接
标题
Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
作者
关键词
Parkinson disease, Biomarkers, Cerebrospinal fluid, Cognitive impairment, Alzheimer's disease, Bone marrow cells, Medical risk factors, Neurofilaments
出版物
PLoS One
Volume 16, Issue 10, Pages e0257372
出版商
Public Library of Science (PLoS)
发表日期
2021-10-08
DOI
10.1371/journal.pone.0257372
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Soluble TREM2 is elevated in Parkinson’s disease subgroups with increased CSF tau
- (2020) Edward N Wilson et al. BRAIN
- Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Sensitivity, Specificity and Potential for Clinical Use
- (2020) Cristina d’Abramo et al. Journal of Personalized Medicine
- Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
- (2019) Isabelle Bos et al. Alzheimers & Dementia
- Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles
- (2019) Richard M. Meade et al. Molecular Neurodegeneration
- Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease
- (2019) Brit Mollenhauer et al. MOVEMENT DISORDERS
- Amyloid-Beta (Aβ) Plaques Promote Seeding and Spreading of Alpha-Synuclein and Tau in a Mouse Model of Lewy Body Disorders with Aβ Pathology
- (2019) Fares Bassil et al. NEURON
- Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
- (2018) Dallas P. Veitch et al. Alzheimers & Dementia
- Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
- (2017) Daniela Bertens et al. Alzheimers Research & Therapy
- Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
- (2017) Chelsea Caspell-Garcia et al. PLoS One
- Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder
- (2016) L.M. Chahine et al. PARKINSONISM & RELATED DISORDERS
- Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease
- (2016) Xiao-Yan Qin et al. JAMA Neurology
- Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
- (2015) Wendy E. Heywood et al. Molecular Neurodegeneration
- The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies
- (2015) Malin Wennström et al. PLoS One
- Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
- (2013) David J. Irwin et al. NATURE REVIEWS NEUROSCIENCE
- Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
- (2012) Irene Litvan et al. MOVEMENT DISORDERS
- APOE ϵ4 Increases Risk for Dementia in Pure Synucleinopathies
- (2012) Debby Tsuang et al. JAMA Neurology
- The Parkinson Progression Marker Initiative (PPMI)
- (2011) Kenneth Marek et al. PROGRESS IN NEUROBIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started